Trial Characteristics	Description/Detail from Report
9. What was the trial’s design (parallel, cross‐over, other etc). (Parallel trial – participants assigned to two or more treatment groups via randomization and remain in allocated group for remainder of trial. Crossover trial – participants are randomized to a particular sequence of treatments and serve as their own control).
10. What was the setting and country of the trial? (Specify specialty (ICU, CCU or CTU etc) and type of hospital or level of trauma centre (tertiary or level I, II or III hospital etc in the country of origin).
11. How was the reference population defined? (i.e. What were the inclusion criteria prior to group allocation?)
12. What were the exclusion criteria before group allocation?
13. Was the sample size justified by a priori calculation of effect size/power? If not, state how study author justified sample size
14. How many people were eligible to participate from the reference population (i.e. those who met inclusion criteria)?